作者: Karl Mann , Henri-Jean Aubin , Katie Witkiewitz
DOI: 10.1159/000481348
关键词:
摘要: Abstinence from alcohol has been the prevailing treatment goal for individuals with dependence (AD) within context of specialty treatment. Yet, use conceptualized as existing on a continuum. Importantly, most people who meet criteria AD and could benefit never receive About half these do not seek because they report desire to continue drinking. To increase acceptability treatment, reductions in consumption have examined alternative outcomes trials AD. The current study reviews data which indicate that long-term reduction among patients is possible. Controlled studies tested reduced show sustained improvements drinking many following behavioral treatments pharmacotherapy. Evidence-based guidelines medicines development guidance authorities taken note developments accept "intermediate harm reduction" (European Medicines Agency) or "low-risk limits" (US Federal Drug Administration) optional trial endpoints. In conclusion, while abstinence remains safest AD, evidence supports approaches may be an important extension